J&J Risperdal Consta “non-approvable”

08 Jul 2002
News

Executive Summary

J&J will discuss FDA concerns about pre-clinical data for injectable long-acting antipsychotic Risperdal Consta (risperidone) following receipt of "non-approvable" letter. J&J filed the NDA Aug. 31, 2001...

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS040127

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS040127

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

J&J Risperdal Consta “non-approvable”

News

Executive Summary

Related Content

J&J Finalizing Risperdal Consta Resubmission; Approval Possible By Year-End

Alkermes Cutbacks Play Well On Wall Street; Biotech Model In Down Market?

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert